Travere Therapeutics appoints Bradley Campbell as President and CEO
Bradley Campbell will be appointed President and CEO of Travere Therapeutics, effective Dec 1.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Travere Therapeutics appoints Bradley L. Campbell CEO effective Dec. 1, 2026
CEO Eric Dube will step down; Bradley L. Campbell appointed president and CEO effective Dec. 1, 2026. Dube will serve as executive advisor through Feb. 15, 2027.